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TO THE EDITOR
Psoriasis is a complex genetic disease,
meaning that a combination of genetic
and environmental risk factors leads to
disease manifestation. The most common
cutaneous manifestation is psoriasis vul-
garis (PV), which is strongly associated
with an HLA-C risk allele located at
psoriasis susceptibility locus 1 (PSORS1).
This locus has a greater impact on PV,
while there are many other genetic risk
factors, contributing far less. Only in some
families and single patients suffering from
PV, as well as in patients with a severe
pustular variant of psoriasis, named gen-
eralized pustular psoriasis (GPP), few
other major genetic risk factors responsi-
ble for those disease manifestations
were identiﬁed. These include missense
variants in CARD14 and loss-of-function
mutations in IL36RN described to be res-
ponsible for PV and GPP or GPP, respec-
tively (Marrakchi et al., 2011; Onoufriadis
et al., 2011; Jordan et al., 2012a, 2012b).
Palmoplantar pustular psoriasis, also
termed palmoplantar pustulosis (PPP), is
characterized by sterile pustules on
the palms and soles. It is more frequent
in women and has stronger associ-
ation with tobacco smoking than PV
or psoriatic arthritis (PsA) (O'Doherty
and MacIntyre, 1985). Although no
randomized controlled studies with bio-
logics licensed for PV have been pub-
lished, conventional therapy is similar to
PV, although there are differences in
therapeutic outcome (Marsland et al.,
2006; De Mozzi et al., 2012). Little is
known about genetic risk factors of PPP;
however, an association of PPP with
missense mutations in IL36RN has been
described recently (Setta-Kaffetzi et al.,
2013). There is an ongoing discussion on
whether PPP is a pustular variant of psori-
asis or a distinct disease entity (Ammoury
et al., 2008; Brunasso et al., 2013).
To characterize PPP genetically, we
recruited a cohort of 251 PPP patients
and screened them for the major genetic
risk factor for PV at PSORS1, as well as
for the two genes IL36RN and CARD14,
as described previously (Huffmeier et al.,
2009; Korber et al., 2013). Approval
for the studies was obtained through
the ethics committees of the respon-
sible universities. Individuals gave their
written informed consent. European
Americans from publicly available
databases, from a previous publication
(Jordan et al., 2012a), and control indivi-
duals from a German cohort (Huffmeier
et al., 2009) served as control groups (for
slight variations in control individuals,
please see Supplementary Information
online). The majority of the 251 PPP
patients was female (78.1%), and 88.4%
of recruited patients had a history of
smoking, with 75% smoking at the
time of their ﬁrst psoriatic manifestation
(Table 1, Supplementary InformationAccepted article preview online 19 May 2015; published online 18 June 2015
Abbreviations: GPP, generalized pustular psoriasis; PPP, palmoplantar pustular psoriasis; PsA, psoriatic
arthritis; PSORS1, psoriasis susceptibility locus 1; PV, psoriasis vulgaris
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online). The percentages of patients with
concomitant PV and a positive family
history for psoriatic manifestations were
16.6% and 32.5%, respectively, and
24.6% of PPP patients reported to have
been diagnosed with PsA.
Four of the 251 PPP patients were
identiﬁed to carry previously identiﬁed
IL36RN mutations by Sanger sequen-
cing (Table 2): one carried c.227C4T/
p.Pro76Leu in a heterozygous form and
three further patients were heterozygous
carriers of c.338C4T/p.Ser113Leu,
summing up to a carrier rate of 2.1%.
In addition, a further patient was hetero-
zygous for c.17C4T/p.Ala6Val, a mis-
sense variant in IL36RN. To the best of
our knowledge, this variant has not
been observed before. Molecular mod-
eling revealed that valine at the sixth
amino acid position causes some minor
local structural changes, but owing to
a neighboring disulﬁde bridge formed
by Cys8, the global structure of the
N terminus can be stabilized. The effect
at the protein level is probably
marginal, and thus the variant was
excluded from further association ana-
lyses. In comparison with different
control groups (Table 2), we observed
no increased frequency of mutant
alleles in IL36RN and therefore no
evidence for association. Previously,
the association of PPP with IL36RN
mutations has been described with
an effect size (odds ratio (OR)) of 12.3
(5.8–25.8; Setta-Kaffetzi et al., 2013).
Our study had 80% power to detect
effects sizes lower than the lower
limit of the 95% conﬁdence interval
in that study. With our cohort, we
had 499.999% power to detect an
association of PPP with IL36RN mutant
alleles based on allele frequency and
effect size reported previously (Setta-
Kaffetzi et al., 2013).
Sequencing of the ﬁrst three coding
exons of CARD14 in 251 PPP patients
revealed several interesting coding
variants: Six heterozygous carriers
of c.599G4A/p.Ser200Asn and two
heterozygous carriers of c.526G4C/p.
Asp176His were identiﬁed (Table 2). In
two different groups of 1,049 controls
genotyped in-house, we identiﬁed
additionally c.536G4A/p.Arg179His
in heterozygous state in one control
individual and 10 heterozygous carriers
of c.599G4A/p.Ser200Asn or
c.526G4C/p.Asp176His. These mis-
sense variants have been previously
described to be involved in PV and
GPP (Jordan et al., 2012a; Korber et al.,
2013; Sugiura et al., 2014). In addition,
we identiﬁed the missense variant
c.589G4A/p.Glu197Lys exclusively in
three German controls, previously
neither reported nor functionally
tested. Therefore, we excluded this
variant from further analyses. With
regard to the three functionally tested
variants and in comparison with
additional publicly available data at
the exome variant server (http://evs.gs.
washington.edu/EVS/), within the 1000
genomes project (Genomes Project
et al., 2010; http://www.1000genomes.
org/) and a previous control cohort of
Table 1. Clinical characteristics of PPP patients
Category Subcategory 251 PPP 217 German PPP 34 Estonian PPP
8 PPP carrying
CARD14 variants
Average age at recruitment 51.1±12.9 50.6± 13.1 54.7±11.1 54.4± 14.5
Average age at ﬁrst psoriatic manifestation 41.8±13.6 41.4± 12.6 49.0±10.2 45.7± 16.9
Gender Male 55 (21.9) 47 (21.7) 8 (23.5) 3 (37.5)
Female 196 (78.1) 170 (78.3) 26 (76.5) 5 (62.5)
Smokers at the time of recruitment Yes 154 (64.4) 137 (66.8) 17 (50.0) 5 (62.5)
No 85 (35.6)1 68 (33.2)1 17 (50.0) 3 (37.5)
Ever smoked Yes 145 (88.4) 123 (94.6) 22 (64.7) 7 (87.5)
No 19 (11.6)2 7 (5.4)2 12 (35.3) 1 (12.5)
Smoking at the time of 1st psoriatic manifestation Yes 173 (74.6) 157 (78.9) 16 (48.5) 6 (75.0)
No 59 (25.4)3 42 (21.1)3 17 (51.5)3 2 (25.0)
Family history positive Yes 75 (32.5) 71 (36.0) 4 (11.8) 1 (14.3)
No 156 (67.5)4 126 (64.0)4 30 (88.2) 6 (85.7)4
Additional PV Yes 41 (16.6) 41 (19.2) 0 (0.0) 1 (12.5)
No 206 (83.4)5 172 (80.8)5 34 (100.0) 7 (87.5)
Additional PsA Yes 59 (24.6) 59 (28.6) 0 (0.0) 2 (28.6)
No 181 (75.4)6 147 (71.4)6 34 (100.0) 5 (71.4)6
Abbreviations: PPP, palmoplantar pustulosis patient; PsA, psoriatic arthritis; PV, psoriasis vulgaris.
Numbers indicate absolute counts (and percentages).
1Unknown status in 12 individuals.
2Unknown status in 81 individuals.
3Unknown status in 19, 18, and 1 individuals, respectively.
4Unknown status in 20, 20, and 1 individuals, respectively.
5Unknown status in 4 individuals.
6Unknown status in 11, 11, and 1 individuals, respectively.
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1,609 control individuals (Jordan et al.,
2012a), we observed a highly signiﬁ-
cant association (P=3.81E-04) and a
corresponding OR of 5.13 (2.08–11.04).
Of note, the effect size is considerably
higher than the effect sizes described in
PV (Jordan et al., 2012a).
Of the eight PPP patients carrying the
three missense variants in CARD14
(Table 1, last column), one patient
(12.5%) had concomitant PV and PsA,
and another patient had concomitant
PsA only. Among the PPP patients,
neither the frequencies of PV and PsA
nor the frequency of patients who had
ever smoked or had a history of smok-
ing differed between carriers and non-
carriers of the three CARD14 missense
variants. Both the percentage of male
patients carrying a CARD14 variant and
the percentage of patients with negative
family history for a psoriatic manifesta-
tion were higher compared with PPP
patients without CARD14 missense var-
iants. However, these results have to be
interpreted with caution owing to the
small size of the groups.
With regard to the PSORS1 risk allele,
we observed no signiﬁcant differences
in carrier frequencies between PPP
patients and healthy controls (Table 2).
We had 80% power to detect an OR of
at least 1.73 given the observed allele
frequency. This effect size is consider-
ably lower than the one observed
previously in our large cohorts of PV
and PsA patients: OR=8.1 (6.5–10.1)
for PV and OR= 4.5 (3.6–5.7) for
PsA. Our negative association ﬁnding
is in concordance with previous studies
(Karvonen et al., 1976; Asumalahti
et al., 2003; Fan et al., 2007).
Overall, our investigations suggest
an involvement of missense variants
in CARD14 in the pathogenesis of
PPP, but do not support a role for
IL36RN mutations. These results suggest
that genetic risk factors in PPP over-
lap with PV and GPP, whereas we
hypothesize that there will be addi-
tional, so far unknown, genetic risk
factors probably restricted to PPP
that are responsible for the typical,
locally restricted palmoplantar pustular
manifestation.
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